Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Treace Medical Concepts's enterprise value is $338.3 Mil.
Treace Medical Concepts's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-45.3 Mil. Therefore, Treace Medical Concepts's EV-to-EBITDA for today is -7.46.
The historical rank and industry rank for Treace Medical Concepts's EV-to-EBITDA or its related term are showing as below:
TMCI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1258.37 Med: -15.04 Max: 1097.78
Current: -7.46
During the past 7 years, the highest EV-to-EBITDA of Treace Medical Concepts was 1097.78. The lowest was -1258.37. And the median was -15.04.
TMCI's EV-to-EBITDA is ranked worse than 100% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.89
vs TMCI: -7.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Treace Medical Concepts (NAS:TMCI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Treace Medical Concepts's PE Ratio (TTM) for today is calculated as:
Treace Medical Concepts's share price for today is $4.785.
Treace Medical Concepts's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Treace Medical Concepts's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Treace Medical Concepts EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Treace Medical Concepts's EV-to-EBITDA falls into.
Treace Medical Concepts's current Enterprise Value is $338.3 Mil.
Treace Medical Concepts's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts (TMCI) has a EV-to-EBITDA of -7.46 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Treace Medical Concepts. According to the industry distribution chart, Treace Medical Concepts ranks #999999 out of 515 companies in the Medical Devices & Instruments industry.
Is Treace Medical Concepts' EV-to-EBITDA too high?
Treace Medical Concepts' current EV-to-EBITDA is -7.46. Based on the distribution chart, Treace Medical Concepts ranks #999999 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Treace Medical Concepts has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Treace Medical Concepts' EV-to-EBITDA compare to TLSI and SENS?
According to the Medical Devices & Instruments industry distribution chart, Treace Medical Concepts ranks #999999 out of 515 companies for EV-to-EBITDA. This places Treace Medical Concepts in the lower half of its industry. The industry median EV-to-EBITDA is 14.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.89, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Treace Medical Concepts. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Treace Medical Concepts's current EV-to-EBITDA is -7.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Treace Medical Concepts stock overvalued right now?
Based on GuruFocus' analysis, Treace Medical Concepts (TMCI) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $4.79 — trading 24.6% below its estimated fair value. The current EV-to-EBITDA is -7.46. Treace Medical Concepts' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Treace Medical Concepts (TMCI), the current EV-to-EBITDA is -7.46 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Treace Medical Concepts (TMCI) Overvalued in 2026?
Based on GuruFocus' analysis, Treace Medical Concepts stock appears to be undervalued.
The current stock price of $4.79 is trading 24.6% below its estimated GF Value™ of $6.35.
GuruFocus considers Treace Medical Concepts to be Modestly Undervalued.
Key valuation signals for TMCI:
EV-to-EBITDA: -7.46
GF Value™: $6.35 vs. price of $4.79 (24.6% below fair value)
No single metric tells the full story. See the TMCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
68GF Score
Get the complete analysis for TMCI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMCI has been successfully added to your 
